Freenome

Freenome's SimpleScreen CRC Data Bolsters Abbott's Colorectal Cancer Screening Market Dominance Prospects

Freenome's updated SimpleScreen CRC test, with improved sensitivity, positions Abbott for market leadership in colorectal cancer screening. This blood-based diagnostic, once FDA-approved, offers a critical alternative to traditional methods, impacting procurement strategies and competitive dynamics. A $70 million milestone payment underscores the commercial significance, driving Abbott's potential dominance in this crucial therapeutic area.